Eubel Brady & Suttman Asset Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-417
| Closed | -$211K | – | 91 |
|
|
2022
Q3 | $211K | Sell |
417
-63
| -13% | -$35.3K | 0.04% | 82 |
|
|
2022
Q2 | $261K | Sell |
480
-14
| -3% | -$7.71K | 0.05% | 67 |
|
|
2022
Q1 | $292K | Sell |
494
-18,011
| -97% | -$10.3M | 0.05% | 64 |
|
|
2021
Q4 | $12.3M | Sell |
18,505
-370
| -2% | -$231K | 2.42% | 19 |
|
|
2021
Q3 | $10.8M | Buy |
18,875
+676
| +4% | +$371K | 2.24% | 25 |
|
|
2021
Q2 | $8.31M | Sell |
18,199
-18,199
| -50% | -$8.59M | 0.73% | 35 |
|
|
2021
Q1 | $16.6M | Buy |
36,398
+18,703
| +106% | +$8.93M | 1.81% | 25 |
|
|
2020
Q4 | $8.24M | Sell |
17,695
-986
| -5% | -$462K | 1.98% | 25 |
|
|
2020
Q3 | $8.25M | Sell |
18,681
-14,402
| -44% | -$5.95M | 2.2% | 24 |
|
|
2020
Q2 | $12M | Sell |
33,083
-393
| -1% | -$132K | 3.15% | 11 |
|
|
2020
Q1 | $9.49M | Sell |
33,476
-249
| -0.7% | -$78.5K | 2.84% | 17 |
|
|
2019
Q4 | $11M | Sell |
33,725
-2,641
| -7% | -$801K | 2.93% | 17 |
|
|
2019
Q3 | $10.6M | Sell |
36,366
-1,601
| -4% | -$458K | 3.04% | 17 |
|
|
2019
Q2 | $11.2M | Sell |
37,967
-1,000
| -3% | -$275K | 3.13% | 13 |
|
|
2019
Q1 | $10.7M | Sell |
38,967
-1,130
| -3% | -$281K | 3.15% | 15 |
|
|
2018
Q4 | $8.97M | Sell |
40,097
-939
| -2% | -$220K | 2.94% | 15 |
|
|
2018
Q3 | $10M | Sell |
41,036
-1,868
| -4% | -$430K | 2.96% | 16 |
|
|
2018
Q2 | $8.89M | Sell |
42,904
-1,318
| -3% | -$280K | 2.75% | 19 |
|
|
2018
Q1 | $9.13M | Sell |
44,222
-601
| -1% | -$126K | 2.9% | 19 |
|
|
2017
Q4 | $8.51M | Sell |
44,823
-10,799
| -19% | -$2.07M | 2.53% | 19 |
|
|
2017
Q3 | $10.5M | Sell |
55,622
-2,550
| -4% | -$462K | 3.23% | 17 |
|
|
2017
Q2 | $10.1M | Sell |
58,172
-3,021
| -5% | -$507K | 3.09% | 16 |
|
|
2017
Q1 | $9.4M | Sell |
61,193
-189
| -0.3% | -$28.9K | 2.82% | 18 |
|
|
2016
Q4 | $8.66M | Sell |
61,382
-961
| -2% | -$142K | 2.6% | 19 |
|
|
2016
Q3 | $9.92M | Sell |
62,343
-938
| -1% | -$145K | 3.13% | 16 |
|
|
2016
Q2 | $9.35M | Sell |
63,281
-1,840
| -3% | -$272K | 3.11% | 16 |
|
|
2016
Q1 | $9.22M | Sell |
65,121
-747
| -1% | -$100K | 3.08% | 18 |
|
|
2015
Q4 | $9.34M | Sell |
65,868
-2,172
| -3% | -$290K | 3.11% | 17 |
|
|
2015
Q3 | $8.32M | Sell |
68,040
-186
| -0.3% | -$24.2K | 2.83% | 19 |
|
|
2015
Q2 | $8.85M | Sell |
68,226
-2,742
| -4% | -$357K | 2.91% | 20 |
|
|
2015
Q1 | $9.53M | Sell |
70,968
-2,076
| -3% | -$268K | 2.92% | 17 |
|
|
2014
Q4 | $9.15M | Sell |
73,044
-2,737
| -4% | -$333K | 2.82% | 21 |
|
|
2014
Q3 | $9.22M | Sell |
75,781
-679
| -0.9% | -$82.6K | 2.75% | 20 |
|
|
2014
Q2 | $9.02M | Sell |
76,460
-875
| -1% | -$103K | 2.59% | 22 |
|
|
2014
Q1 | $9.3M | Sell |
77,335
-4,038
| -5% | -$480K | 2.63% | 19 |
|
|
2013
Q4 | $9.06M | Sell |
81,373
-4,984
| -6% | -$496K | 2.61% | 17 |
|
|
2013
Q3 | $7.96M | Sell |
86,357
-6,243
| -7% | -$565K | 2.17% | 26 |
|
|
2013
Q2 | $7.84M | Buy |
+92,600
| New | +$7.71M | 2.15% | 26 |
|
Other funds holding TMO
Eubel Brady & Suttman Asset Management's TMO Position: Q4 2022 in Review
Eubel Brady & Suttman Asset Management sold out of Thermo Fisher Scientific (TMO) in Q4 2022, closing a stake of 417 shares — an estimated $211K sold.
Eubel Brady & Suttman Asset Management first reported a position in TMO in Q2 2013 and held it in 38 quarters. The position peaked at $16.6M in Q1 2021. 2,375 funds tracked by Wall St. Rank hold TMO as of Q4 2022.
- Eubel Brady & Suttman Asset Management reported no remaining Thermo Fisher Scientific position as of Q4 2022 after selling out during the quarter.
- Eubel Brady & Suttman Asset Management sold 417 Thermo Fisher Scientific shares in Q4 2022, an estimated $211K.
- Eubel Brady & Suttman Asset Management first reported a position in Thermo Fisher Scientific in Q2 2013 and held it in 38 quarters.
- Eubel Brady & Suttman Asset Management's Thermo Fisher Scientific position peaked at $16.6M in Q1 2021.
- 2,375 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2022.
Based on Eubel Brady & Suttman Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.